Pulmonary delivery of mucosal nanovaccines.
Pulmonary delivery of mucosal nanovaccines.
复制标题
粘膜纳米疫苗的肺部给药。
DOI：
10.1039/d1nr06512b
复制
发表时间：
2022-01-06
期刊：
影响因子：
6.7
通讯作者：
Zhu G
中科院分区：
文献类型：
--
作者：
Tang W;Zhang Y;Zhu G
粘膜疫苗接种可以引起全身免疫和粘膜免疫，因此不仅可以治疗粘膜免疫疾病，预防粘膜进入部位的病原体感染，还可以治疗远处或全身免疫疾病。然而，只有少数粘膜疫苗被批准用于临床人类使用。有效的粘膜免疫需要将免疫原性试剂递送至适当的粘膜表面，由于粘膜组织中存在重要的生物屏障，这仍然具有很大的挑战性。过去十年，肺粘膜纳米疫苗的研发取得了显着进展。纳米疫苗利用先进的基于纳米粒子的肺部输送技术，利用肺部大表面积和丰富的抗原呈递细胞环境的特点，触发针对各种粘膜疾病的强大免疫保护。在此，我们回顾了当前的肺部递送方法和配方，讨论了用于有效和持久免疫反应的粘膜纳米疫苗的设计策略，并重点介绍了基于脂质的肺部纳米疫苗在对抗粘膜疾病中的应用的最新进展。这些进展有望加速新型粘膜纳米疫苗的开发，用于预防和治疗传染病、癌症以及粘膜组织的自身免疫性疾病。粘膜疫苗可以引发全身和粘膜免疫，以治疗/预防局部粘膜或远处或全身免疫疾病和感染。
Mucosal vaccination can elicit both systemic and mucosal immunity, and therefore has the potential to not only treat mucosal immune diseases, prevent the pathogen infection at the mucosal entry sites, but also treat distant or systemic immune disorders. However, only a few mucosal vaccines have been approved for human use in the clinic. Effective mucosal immunization requires the delivery of immunogenic agents to appropriate mucosal surfaces, which remains significantly challenging due to the essential biological barriers presenting at mucosal tissues. In the past decade, remarkable progress has been made in the development of pulmonary mucosal nanovaccines. The nanovaccines leverage advanced nanoparticle-based pulmonary delivery technologies on the characteristics of large surface area and rich antigen presentation cell environment of the lungs for triggering robust immune protection against various mucosal diseases. Herein, we review current methods and formulations of pulmonary delivery, discuss the design strategies of mucosal nanovaccines for potent and long-lasting immune responses, and highlight recent advances in the application of lipid-based pulmonary nanovaccines against mucosal diseases. These advances promise to accelerate the development of novel mucosal nanovaccines for the prophylaxis and therapy of infectious diseases, and cancer, as well as autoimmune disorders at mucosal tissues. Mucosal vaccines can elicit both systemic and mucosal immunity to treat/prevent local mucosal or distant or systemic immune diseases and infection.
登录
查看更多内容
影响因子：
17.1
作者：
Kirkpatrick JD;Warren AD;Soleimany AP;Westcott PMK;Voog JC;Martin-Alonso C;Fleming HE;Tammela T;Jacks T;Bhatia SN
通讯作者：
Bhatia SN
粘膜疫苗：策略与挑战
影响因子：
4.4
作者：
Li, Miao;Wang, Yi;Qiu, Hua-Ji
通讯作者：
Qiu, Hua-Ji
DOI：
10.1002/anie.202101732
发表时间：
2021-07-05
期刊：
Angewandte Chemie (International ed. in English)
影响因子：
--
作者：
Chen D;Liu S;Chen D;Liu J;Wu J;Wang H;Su Y;Kwak G;Zuo X;Rao D;Cui H;Shu C;Suk JS
通讯作者：
Suk JS
影响因子：
16.1
作者：
Lai, Samuel K.;Wang, Ying-Ying;Hanes, Justin
通讯作者：
Hanes, Justin
影响因子：
7.8
作者：
Buschmann MD;Carrasco MJ;Alishetty S;Paige M;Alameh MG;Weissman D
通讯作者：
Weissman D